Indiana Medicaid spending on GLP-1 drugs
How much did Indiana Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?
Pharmacies were reimbursed at least $204.8 million for GLP-1 drugs paid through Indiana Medicaid in 2025, across at least 190,162 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 82 rows of 297, so these figures are floors.
Pharmacies were reimbursed at least $46.4 million for GLP-1 drugs paid through Indiana Medicaid in 2026 (quarter 1 only, as posted so far), across at least 41,444 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 19 rows of 82, so these figures are floors.
By year and ingredient
| 2020 | at least $20,254,059 | No data | at least $20,302,665 | at least $13,204,457 | at least $4,143,465 | Suppressed | at least $225,150 | at least $90,258 | at least $58,220,054 |
| 2021 | at least $40,050,400 | No data | $20,087,410 | at least $27,487,519 | at least $3,825,421 | Suppressed | at least $271,991 | at least $86,652 | at least $91,809,392 |
| 2022 | at least $67,006,099 | at least $3,384,724 | $9,763,308 | at least $49,200,838 | at least $5,885,130 | Suppressed | at least $303,952 | at least $88,335 | at least $135,632,387 |
| 2023 | at least $105,945,078 | at least $25,133,174 | at least $6,630,693 | at least $54,610,078 | at least $6,290,364 | No data | at least $360,267 | at least $82,040 | at least $199,051,693 |
| 2024 | at least $143,918,036 | at least $28,607,460 | at least $2,688,895 | at least $34,163,106 | at least $935,098 | No data | at least $229,183 | Suppressed | at least $210,541,778 |
| 2025 | at least $151,406,860 | at least $21,445,630 | at least $819,590 | at least $30,812,313 | at least $118,436 | No data | at least $161,175 | Suppressed | at least $204,764,005 |
| 2026 (Q1) | at least $31,603,949 | at least $8,185,632 | at least $164,365 | $6,432,767 | No data | No data | at least $26,817 | No data | at least $46,413,529 |
By product, 2025
| Ozempic | at least $145,777,798 | at least 135,539 | 10 of 36 |
| Rybelsus | at least $1,188,645 | at least 980 | 8 of 24 |
| Wegovy | at least $4,440,417 | at least 3,297 | 5 of 40 |
| Mounjaro | at least $15,825,936 | at least 13,709 | 1 of 48 |
| Zepbound | at least $5,619,694 | at least 5,452 | 14 of 36 |
| Liraglutide (generic name listing) | at least $492,378 | at least 1,307 | 19 of 40 |
| Saxenda | Suppressed | Suppressed | 5 of 5 |
| Victoza | at least $327,213 | at least 550 | 4 of 12 |
| Trulicity | at least $30,812,313 | at least 29,049 | 3 of 35 |
| Bydureon | at least $67,906 | at least 79 | 1 of 3 |
| Byetta | at least $50,531 | at least 51 | 2 of 4 |
| Exenatide (generic name listing) | Suppressed | Suppressed | 3 of 3 |
| Soliqua | at least $161,175 | at least 149 | 4 of 8 |
| Xultophy | Suppressed | Suppressed | 3 of 3 |
By quarter, 2025
| Q1 2025 | at least $52,838,081 | at least 48,292 | 24 of 73 |
| Q2 2025 | at least $51,362,146 | at least 48,315 | 23 of 74 |
| Q3 2025 | at least $51,220,002 | at least 47,929 | 18 of 74 |
| Q4 2025 | at least $49,343,776 | at least 45,626 | 17 of 76 |
By quarter, 2026 (posted so far)
| Q1 2026 | at least $46,413,529 | at least 41,444 | 19 of 82 |
The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:
“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”
Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”
CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.
Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.
Sources
- CMS Medicaid State Drug Utilization Data (Medicaid.gov)
- State Drug Utilization Data 2020 (data.medicaid.gov)
- State Drug Utilization Data 2021 (data.medicaid.gov)
- State Drug Utilization Data 2022 (data.medicaid.gov)
- State Drug Utilization Data 2023 (data.medicaid.gov)
- State Drug Utilization Data 2024 (data.medicaid.gov)
- State Drug Utilization Data 2025 (data.medicaid.gov)
- State Drug Utilization Data 2026 (data.medicaid.gov)
Records last pulled Nov 15, 2026. Every entry links to the original public record.